Temasek, a global investment company headquartered in Singapore, led a €255m funding round in ITM Isotope Technologies Munich, a radiopharmaceutical biotech company, with participation from BlackRock, Qatar Investment Authority, Nextech, ATHOS and Carbyne. "ITM is a leading radiopharmaceutical company with an advanced proprietary pipeline and has established itself as the major radioisotope supplier globally. This financing supports our objective to serve a broad patient population by ensuring a consistent supply of radionuclides and radiopharmaceuticals to meet the growing demand of medical professionals and our partners across the pharmaceutical, healthcare and research sectors globally," Udo J. Vetter, ITM Chairman of the Supervisory Board.